Literature DB >> 28075458

Silencing of Forkhead box D1 inhibits proliferation and migration in glioma cells.

Yuan-Feng Gao1, Tao Zhu1, Xiao-Yuan Mao1, Chen-Xue Mao1, Ling Li1, Ji-Ye Yin1, Hong-Hao Zhou1, Zhao-Qian Liu1.   

Abstract

Despite the extensive role of Forkhead box transcription factors in the development and progression of various cancers, little is known about their role in glioma. We examined the expression and function of Forkhead box D1 (FOXD1) in glioma cell behavior and found that FOXD1 was upregulated and directly correlated with the glioma grade. Data analysis also revealed significant differences in FOXD1 expression for both gene expression profiles (GSE4290 and GSE7696) and the TCGA datasets. Additionally, decreased FOXD1 expression in U251 and U87 glioma cells caused a delay in cell growth and a disruption in colony formation. FOXD1 silencing also promoted generation of apoptotic bodies containing nuclear fragments. Cells with suppressed expression of FOXD1 markedly reduced glioma cell migration. Our results suggest that FOXD1 may serve as a novel regulator of glioblastoma cell behavior that may offer a novel target for gene targeted glioma therapies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28075458     DOI: 10.3892/or.2017.5344

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  FOXD1 predicts prognosis of colorectal cancer patients and promotes colorectal cancer progression via the ERK 1/2 pathway.

Authors:  Fengping Pan; Minjiang Li; Wenbin Chen
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 2.  The multisystemic functions of FOXD1 in development and disease.

Authors:  Paula Quintero-Ronderos; Paul Laissue
Journal:  J Mol Med (Berl)       Date:  2018-06-29       Impact factor: 4.599

3.  LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway.

Authors:  Liping Wu; Yongcun Liu; Cheng Guo; Yuan Shao
Journal:  Cancer Cell Int       Date:  2020-07-09       Impact factor: 5.722

4.  Nucleolar and spindle-associated protein 1 is a tumor grade correlated prognosis marker for glioma patients.

Authors:  Tao Zhu; Pan Xie; Yuan-Feng Gao; Ma-Sha Huang; Xi Li; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2018-01-15       Impact factor: 5.243

5.  MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.

Authors:  Xin-Long Ma; Feng Shang; Wei Ni; Jin Zhu; Bin Luo; Yu-Qi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-09-17       Impact factor: 4.553

6.  FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.

Authors:  Huazhen Liang; Chunning Zhang; Chaoming Li; Changguo Li; Yanli Wang; Huaming Lin
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

7.  Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient.

Authors:  Christopher A Miller; Sonika Dahiya; Tiandao Li; Robert S Fulton; Matthew D Smyth; Gavin P Dunn; Joshua B Rubin; Elaine R Mardis
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

8.  CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.

Authors:  Chun Chen; Zhuo-Qing Xu; Ya-Ping Zong; Bao-Chi Ou; Xiao-Hui Shen; Hao Feng; Min-Hua Zheng; Jing-Kun Zhao; Ai-Guo Lu
Journal:  Cell Death Dis       Date:  2019-02-21       Impact factor: 8.469

9.  Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.

Authors:  Liangjing Zhou; Shengnan Jia; Guoping Ding; Mingjie Zhang; Weihua Yu; Zhengrong Wu; Liping Cao
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

10.  Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma.

Authors:  Jessica Tome-Garcia; Parsa Erfani; German Nudelman; Alexander M Tsankov; Igor Katsyv; Rut Tejero; Martin Walsh; Roland H Friedel; Elena Zaslavsky; Nadejda M Tsankova
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.